Rituximab is a monoclonal antibody that targets and depletes CD20+ B cells and, in combination with methotrexate, is approved for the treatment of RA in patients who have had an inadequate response to ≥1 tumor necrosis factor inhibitor (TNFi). Here, TNF is linked to rheumatoid arthritis.